subscribeSubscribe
PLOS ONE Publishes Data on Allarity DRP® Companion Diagnostic for Dovitinib

PLOS ONE Publishes Data on Allarity DRP® Companion Diagnostic for Dovitinib
GLOBENEWSWIRE
30 Aug 2023
Share Share
Allarity Doses First Patient in Ph1b Trial Evaluating Dovitinib and Stenoparib

Allarity Doses First Patient in Ph1b Trial Evaluating Dovitinib and Stenoparib
GLOBENEWSWIRE
20 Mar 2023
Share Share
FDA sinks Allarity’s plans for lead oncology asset

FDA sinks Allarity’s plans for lead oncology asset
Gabrielle Masson FIERCEBIOTECH
03 Aug 2022
Share Share
Allarity Therapeutics partners with Lonza to manufacture Dovitinib

Allarity Therapeutics partners with Lonza to manufacture Dovitinib
PHARMAFILE
23 Sep 2021
Share Share
Allarity Presents Dovitinib Survival Data from DRP® Screened RCC Patients

Allarity Presents Dovitinib Survival Data from DRP® Screened RCC Patients
GLOBENEWSWIRE
16 Sep 2021
Share Share
Allarity Therapeutics Receives Acceptance & Review Notification From USFDA

Allarity Therapeutics Receives Acceptance & Review Notification From USFDA
GLOBENEWSWIRE
05 Jul 2021
Share Share
Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib

Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib
GLOBENEWSWIRE
14 Jun 2021
Share Share
Allarity Therapeutics Provides Update on Dovitinib Program

Allarity Therapeutics Provides Update on Dovitinib Program
GLOBENEWSWIRE
23 Oct 2020
Share Share
Press release Oncology Venture acquires full control of Dovitinib program

Press release Oncology Venture acquires full control of Dovitinib program
GLOBENEWSWIRE
08 Jun 2020
Share Share
Dovitinib LiPlaCis data to support FDA breakthrough designation strategy

Dovitinib LiPlaCis data to support FDA breakthrough designation strategy
GLOBENEWSWIRE
07 Feb 2019
Share Share